Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 08, 2016 4:41 AM ET


Company Overview of NanoBio Corporation

Company Overview

NanoBio Corporation, a biopharmaceutical company, focused on developing and commercializing intranasal and intramuscular vaccines. The company offers vaccines targeting respiratory, sexually transmitted, and other diseases. It offers NanoStat Platform that utilizes a novel oil-in-water emulsion adjuvant to enable vaccines that elicit broad protection against disease. The company’s lead product candidates include vaccines for RSV, herpes simplex virus-2, H5 influenza, human immunodeficiency virus, seasonal and pandemic influenza, pertussis, and anthrax. It has a strategic alliance with Merck & Co., Inc. NanoBio Corporation was founded in 1999 and is based in Ann Arbor, Michigan.

2311 Green Road

Suite A

Ann Arbor, MI 48105

United States

Founded in 1999





Key Executives for NanoBio Corporation

Chief Executive Officer and Director
Age: 45
Senior Vice President of Vaccine Research and Development
Member of Scientific Team
Director of Formulations
Compensation as of Fiscal Year 2015.

NanoBio Corporation Key Developments

NanoBio Corporation Announces Licensing Agreement with a Subsidiary of Merck & Co., Inc

NanoBio Corporation announced a licensing agreement with a subsidiary of Merck & Co. Inc., known as MSD outside the United States and Canada, for the use of its nanoemulsion (NE) adjuvant technology. Under the agreement, Merck receives exclusive rights to NanoBio's NE adjuvant for use in an intranasal respiratory syncytial virus (RSV) vaccine and non-exclusive rights for use in an intranasal seasonal influenza and/or universal seasonal influenza ("Flu") vaccine. NanoBio receives an upfront payment and is eligible to receive milestone payments based on Merck RSV and Flu vaccine candidates' development and regulatory approvals, as well as royalties on sales of any Merck RSV or Flu vaccines that ultimately use the NanoBio NE adjuvant technology. NanoBio's NanoStat(R) technology platform employs a novel oil-in-water nanoemulsion that can incorporate, deliver and adjuvant multiple antigen types. The NE adjuvant is effective when administered via intranasal, intramuscular or subcutaneous vaccination. In recent studies, NanoBio has demonstrated that intranasal vaccination elicits robust systemic and mucosal immunity, thereby offering enhanced protection against respiratory infections and sexually transmitted diseases compared to intramuscular vaccination.

Similar Private Companies By Industry

Company Name Region
Lycera Corp. United States
Damage Control Technologies, Inc. United States
Warner Chilcott Finance LLC United States
Astellas Pharma Manufacturing, Inc. United States
Cheerz USA Inc. United States

Recent Private Companies Transactions

Private Placement
December 22, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact NanoBio Corporation, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at